Paul M. Sondel, MD, PhD Print Friendly Page
Faculty, University of Wisconsin School of Medicine and Public HealthPaul Sondel, M.D., Ph.D. is the Reed and Carolee Walker Professor in Pediatric Oncology at the University of Wisconsin – Madison.
Dr. Sondel, a Milwaukee native, completed undergraduate and graduate education at UW-Madison leading to a Ph.D. in Genetics (1975), with guidance from Bone Marrow Transplant pioneer, Fritz Bach, M.D. He received his M.D. magna cum laude in 1977 from Harvard Medical School, while beginning his research in tumor immunology. Following pediatric residency training at the Universities of Minnesota and Wisconsin, he joined the faculty of UW-Madison in 1980 in the Departments of Pediatrics, Human Oncology and Genetics. He was promoted to professor in 1987, and became leader of the UW Carbone Cancer Center's Program in Immunology and Immunotherapy in 1990, when he also became Head of the Division of Pediatric Oncology.
Dr. Sondel has been a leader in scientific policy through multiple national committee roles, including The National Institutes of Health, The American Cancer Society, The Children's Oncology Group (COG), The National Cancer Institute, where he was a member of the Board of Scientific Counselors, and St. Jude's Children’s Research Hospital, where he was the Chair of their Scientific Advisory Committee and is now chair of their cancer center's external advisory board.
Clinically, he has worked with COG in contributing to the progress of the past 30 years in the development of curative treatments for childhood cancers. He is devoted to his own patients, and committed to leading a multidisciplinary team that is providing comprehensive and compassionate, state of the art treatment for all childhood cancer and hematology patients at the University of Wisconsin.
Specialties
Clinics
American Family Children's Hospital
(608) 263-6420 | (800) 323-8942 | Map
UW School of Medicine and Public Health
| Department of Pediatrics |
Professional Certifications and Education
| Board Certification |
Pediatrics
|
| Fellowship |
Pediatric Oncology, Midwest Children's Cancer Center at Children's Hospital of Wisconsin, Milwaukee, WI |
| Residency |
University of Wisconsin Hospital and Clinics, Madison, WI
|
| Internship |
University of Minnesota Affiliated Hospitals, Minneapolis, MN
|
| Medical School |
Harvard Medical School, Boston, MA
|
| Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000. |
| Research |
Dr. Sondel's research has emphasized the translation of laboratory innovations into clinical progress. His laboratory has pursued the biology of graft-versus-leukemia reactions, activation of anti-tumor immune destruction with Interleukin-2 and the use of tumor reactive monoclonal antibodies to facilitate tumor killing by lymphocytes. These studies have all moved into clinical testing led by Dr. Sondel at UW, and in national studies he has led through the Children’s Oncology Group (COG).
He has published more than 360 scientific articles and chapters, and his laboratory has provided training for 58 graduate students and post-doctoral fellows. Learn more about Dr. Sondel's research: UW-Madison Department of Genetics | Sondel Laboratory |
PubMed Articles
-
Felder M Kapur A Rakhmilevich AL Qu X Sondel PM Gillies SD Connor J Patankar MS
MUC16 suppresses human and murine innate immune responses. Gynecol Oncol . 2019 Jan 6;
[PubMed ID: 30626487]
-
Ayuso JM Truttschel R Gong MM Humayun M Virumbrales-Munoz M Vitek R Felder M Gillies SD Sondel P Wisinski KB Patankar M Beebe DJ Skala MC
Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model. Oncoimmunology . 2019;8(3):1553477
[PubMed ID: 30723584]
-
Wei JS Kuznetsov IB Zhang S Song YK Asgharzadeh S Sindiri S Wen X Patidar R Najaraj S Walton A Auvil JMG Gerhard DS Yuksel A Catchpoole D Hewitt SM Sondel PM Seeger R Maris JM Khan J
Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk <i>MYCN</i>-Not-Amplified Human Neuroblastoma. Clin Cancer Res . 2018 Nov 15;24(22):5673-5684
[PubMed ID: 29784674]
-
Albertini MR Yang RK Ranheim EA Hank JA Zuleger CL Weber S Neuman H Hartig G Weigel T Mahvi D Henry MB Quale R McFarland T Gan J Carmichael L Kim K Loibner H Gillies SD Sondel PM
Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunol Immunother . 2018 Oct;67(10):1647-1658
[PubMed ID: 30073390]
-
Ozkaynak MF Gilman AL London WB Naranjo A Diccianni MB Tenney SC Smith M Messer KS Seeger R Reynolds CP Smith LM Shulkin BL Parisi M Maris JM Park JR Sondel PM Yu AL
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Front Immunol . 2018;9:1641
[PubMed ID: 30046297]
-
Morris ZS Guy EI Werner LR Carlson PM Heinze CM Kler JS Busche SM Jaquish AA Sriramaneni RN Carmichael LL Loibner H Gillies SD Korman AJ Erbe AK Hank JA Rakhmilevich AL Harari PM Sondel PM
Tumor-Specific Inhibition of <i>In Situ</i> Vaccination by Distant Untreated Tumor Sites. Cancer Immunol Res . 2018 Jul;6(7):825-834
[PubMed ID: 29748391]
-
Ozkaynak MF Gilman AL London WB Naranjo A Diccianni MB Tenney SC Smith M Messer KS Seeger R Reynolds CP Smith LM Shulkin BL Parisi M Maris JM Park JR Sondel PM Yu AL
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Front Immunol . 2018;9:1355
[PubMed ID: 29967609]
-
Bristow RG Alexander B Baumann M Bratman SV Brown JM Camphausen K Choyke P Citrin D Contessa JN Dicker A Kirsch DG Krause M Le QT Milosevic M Morris ZS Sarkaria JN Sondel PM Tran PT Wilson GD Willers H Wong RKS Harari PM
Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. Lancet Oncol . 2018 May;19(5):e240-e251
[PubMed ID: 29726389]
-
Miller JS Morishima C McNeel DG Patel MR Kohrt HEK Thompson JA Sondel PM Wakelee HA Disis ML Kaiser JC Cheever MA Streicher H Creekmore SP Waldmann TA Conlon KC
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. Clin Cancer Res . 2018 Apr 1;24(7):1525-1535
[PubMed ID: 29203590]
-
Erbe AK Wang W Carmichael L Kim K Mendonça EA Song Y Hess D Reville PK London WB Naranjo A Hank JA Diccianni MB Reisfeld RA Gillies SD Matthay KK Cohn SL Hogarty MD Maris JM Park JR Ozkaynak MF Gilman AL Yu AL Sondel PM
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clin Cancer Res . 2018 Jan 1;24(1):189-196
[PubMed ID: 28972044]
-
Ascierto PA Agarwala SS Ciliberto G Demaria S Dummer R Duong CPM Ferrone S Formenti SC Garbe C Halaban R Khleif S Luke JJ Mir LM Overwijk WW Postow M Puzanov I Sondel P Taube JM Thor Straten P Stroncek DF Wargo JA Zarour H Thurin M
Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. J Transl Med . 2017 Nov 16;15(1):236
[PubMed ID: 29145885]
-
Masucci GV Cesano A Eggermont A Fox BA Wang E Marincola FM Ciliberto G Dobbin K Puzanov I Taube J Wargo J Butterfield LH Villabona L Thurin M Postow MA Sondel PM Demaria S Agarwala S Ascierto PA
The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. J Transl Med . 2017 Nov 3;15(1):223
[PubMed ID: 29100546]
-
Federico SM McCarville MB Shulkin BL Sondel PM Hank JA Hutson P Meagher M Shafer A Ng CY Leung W Janssen WE Wu J Mao S Brennan RC Santana VM Pappo AS Furman WL
A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma. Clin Cancer Res . 2017 Nov 1;23(21):6441-6449
[PubMed ID: 28939747]
-
Mody R Naranjo A Van Ryn C Yu AL London WB Shulkin BL Parisi MT Servaes SE Diccianni MB Sondel PM Bender JG Maris JM Park JR Bagatell R
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol . 2017 Jul;18(7):946-957
[PubMed ID: 28549783]
-
Erbe AK Wang W Reville PK Carmichael L Kim K Mendonca EA Song Y Hank JA London WB Naranjo A Hong F Hogarty MD Maris JM Park JR Ozkaynak MF Miller JS Gilman AL Kahl B Yu AL Sondel PM
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Front Immunol . 2017;8:675
[PubMed ID: 28659916]
-
Erbe AK Wang W Goldberg J Gallenberger M Kim K Carmichael L Hess D Mendonca EA Song Y Hank JA Cheng SC Signoretti S Atkins M Carlson A Mier JW Panka DJ McDermott DF Sondel PM
FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clin Cancer Res . 2017 May 1;23(9):2159-2168
[PubMed ID: 27742794]
-
Wang W Erbe AK DeSantes KB Sondel PM
Donor selection for ex vivo-expanded natural killer cells as adoptive cancer immunotherapy. Future Oncol . 2017 May;13(12):1043-1047
[PubMed ID: 28492088]
-
Rakhmilevich AL Felder M Lever L Slowinski J Rasmussen K Hoefges A Van De Voort TJ Loibner H Korman AJ Gillies SD Sondel PM
Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model. J Immunol . 2017 Feb 15;198(4):1575-1584
[PubMed ID: 28062694]
-
Wang W Erbe AK Gallenberger M Kim K Carmichael L Hess D Mendonca EA Song Y Hank JA Cheng SC Signoretti S Atkins M Carlson A Weiss JM Mier J Panka D McDermott DF Sondel PM
Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. Cancer Immunol Immunother . 2016 Dec;65(12):1523-1532
[PubMed ID: 27695964]
-
Wang W Erbe AK Alderson KA Phillips E Gallenberger M Gan J Campana D Hank JA Sondel PM
Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion. Cancer Immunol Immunother . 2016 Sep;65(9):1047-59
[PubMed ID: 27392940]